EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cancer prevalence in primary mitochondrial disease patients and their families

Shrey Dalwadi iD, Nicole M Engelhardt, Colleen C Muraresku iD, Kelsey Keith iD, Kathleen D Valverde, Katherine L Nathanson, Marni J Falk

Therapeutic Advances in Rare Disease · 2026-07 · 7

DOI: 10.1177/26330040261471914 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Rare Disease, online erschienen am 29.07.2026. Verfasst von Shrey Dalwadi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Mitochondrial Medicine Frontier Program, Division of Genetic and Genomic Medicine, Department of Pediatrics, The Children's Hospital of Philadelphia,…. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: children’s hospital of philadelphia, United Mitochondrial Disease Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While somatic mitochondrial dysfunction occurs in diverse cancers, the association between oncogenesis and germline mitochondrial gene pathogenic variants remains unclear. Further, few clinical observations have been reported of cancer occurring in primary mitochondrial disease (PMD) patients.

Objectives

To improve understanding of the potential modulating role for PMD gene disorders in cancer prevalence.

Design

727 individuals, including 100 with PMD, from 97 unrelated families were retrospectively surveyed to assess their history of individual cancer occurrence.

Methods

We evaluated survey responses by characterizing the cancer prevalence among the study cohort and comparing to the general U.S. population via the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) database. Odds ratio calculation was performed to determine the association of survey responses and cancer prevalence.

Results

Although overall cancer prevalence in PMD probands and their families was elevated compared to the NCI SEER rate (8800 vs 5600 cases per 100,000), odds ratio calculation determined that PMD did not significantly increase the likelihood of developing cancer, with a non-significant trend observed toward less cancer occuring in PMD that needs to be explored in further studies. Cancer prevalence was significantly correlated with advanced age. Significantly reduced prevalence of prostate cancer was seen across the entire cohort. Surprisingly, while low absolute prevalence ( n = 3), a 9-fold increased odds ratio of cancer was seen in POLG patients relative to those with other causes of PMD.

Conclusion

No evidence of increased cancer odds was identified in a cohort of PMD patients and their close relatives. Interestingly, a possible inverse association, which did not reach statistical significance, was suggested between mitochondrial disease status and cancer odds. Future prospective investigations in larger PMD kindreds are warranted to validate and evaluate potential mechanistic relations between cancer prevalence and PMD.

Schlagwörter

Stichwörter der Autor:innen

POLGcancermitochondriaprimary mitochondrial disease

Autor:innen und Institutionen

  • Mitochondrial Medicine Frontier Program, Division of Genetic and Genomic Medicine, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Cooper Medical School of Rowan University, Camden, NJ, USA.
  • Division of Genetic and Genomic Medicine, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

ORCID-Profile: Shrey Dalwadi, Colleen C Muraresku, Kelsey Keith

Förderung

  • children’s hospital of philadelphia
  • United Mitochondrial Disease Foundation

Zitieren

APA

Dalwadi, S., Engelhardt, N. M., Muraresku, C. C., Keith, K., Valverde, K. D., Nathanson, K. L., & Falk, M. J. (2026). Cancer prevalence in primary mitochondrial disease patients and their families. Therapeutic Advances in Rare Disease, 7. https://doi.org/10.1177/26330040261471914

Vancouver

Dalwadi S, Engelhardt NM, Muraresku CC, Keith K, Valverde KD, Nathanson KL, et al. Cancer prevalence in primary mitochondrial disease patients and their families. Therapeutic Advances in Rare Disease. 2026;7. doi:10.1177/26330040261471914

BibTeX
@article{Dalwadi2026,
  author = {Dalwadi, Shrey and Engelhardt, Nicole M and Muraresku, Colleen C and Keith, Kelsey and Valverde, Kathleen D and Nathanson, Katherine L and Falk, Marni J},
  title = {Cancer prevalence in primary mitochondrial disease patients and their families},
  journal = {Therapeutic Advances in Rare Disease},
  year = {2026},
  volume = {7},
  doi = {10.1177/26330040261471914}
}
Kostenlos starten →